News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark`s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat�2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254]. According to IQVIA� sales data for the 12-month period ending April 2026, the Vimpat� Injection market3 achieved annual sales of approximately $15.2 million. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, �The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.�

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.

Net profit of Glenmark Pharmaceuticals rose 6381.94% to Rs 301.41 crore in the quarter ended March 2026 as against Rs 4.65 crore during the previous quarter ended March 2025. Sales rose 16.77% to Rs 3760.28 crore in the quarter ended March 2026 as against Rs 3220.13 crore during the previous quarter ended March 2025.For the full year,net profit rose 30.06% to Rs 1361.85 crore in the year ended March 2026 as against Rs 1047.10 crore during the previous year ended March 2025. Sales rose 27.12% to Rs 16711.40 crore in the year ended March 2026 as against Rs 13145.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3760.283220.13 17 16711.4013145.84 27 OPM %20.2817.42 -27.3617.89 - PBDT909.08506.00 80 4824.312258.04 114 PBT761.17380.79 100 4250.831772.03 140 NP301.414.65 6382 1361.851047.10 30 Powered by Capital Market - Live News

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark`s Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC. According to IQVIA� sales data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market2 achieved annual sales of approximately $37.9 million.